Women’s Health Initiative (WHI) Clinical Trials (CT) Observational Study (OS) Diet Modification (DM) Hormone Replacement Therapy (HRT) Calcium +Vitamin.

Slides:



Advertisements
Similar presentations
Women's Health Initiative
Advertisements

JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS Miller P, et al. J Acad Nutr Diet. 2012; 112 (June). Dietary Patterns Differ between Urban & Rural Older,
K. HERT, M.G. WAGNER, L. MYERS, J. LEVINE*, T. HECK, Y. RHEE HEALTH, NUTRITION, AND EXERCISE SCIENCES, NORTH DAKOTA STATE UNIVERSITY, FARGO, ND, *FAMILY.
Women’s Health Initiative - Summary of results DISCLAIMER Menopausetoday gives the following presentation for your information and.
The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
10 Points to Remember for the Management of Overweight and Obesity in Adults Management of Overweight and Obesity in Adults Summary Prepared by Elizabeth.
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
UNIVERSITY OF CAMBRIDGE
Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
The Diabetes Prevention Program A U.S. Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs)
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Physical Activity and Reduction of Colon Cancer Risk.
National Institutes of Health National Heart, Lung, and Blood Institute Women’s Health Initiative (WHI) Clinical Trials (Diet, Hormones, Calcium/Vit D)
Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy The Women’s Health Initiative Randomized Controlled Trial JAMA 2004;291:
Research Design: RCT and Cohort Studies John Q. Wong, MD, MSc 22 Jun 2010.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
Breast Health Guysborough Antigonish Strait Health Authority With support from: Canadian Breast Cancer Foundation – Atlantic Chapter Marvelle Koffler Breast.
Linda Snetselaar, PhD, RD Professor Interim Chair of the Department of Community and Behavioral Health College of Public Health University of Iowa.
April Back to Basics, 2011 POPULATION HEALTH: Periodic Health Exam, Epidemiology & Community Medicine Based on slides prepared by Dr. R. Spasoff.
JANET P. PREGLER, MD; CAROLYN J. CRANDALL, MD, MS. ANNALS OF INTERNAL MEDICINE. 2011; 155: JULIANNA L. MURPHY PHARM.D. CANDIDATE PRECEPTOR: ALI RAHIMI,
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Ramón Estruch, M.D., Ph.D., …and 18 others for PREDIMED study investigators Published:
A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians’ Health Study II HD Sesso, WC Christen, V Bubes,
Hormonal Replacement Therapy for postmenopausal females: To give or not to give? Amna B. Buttar, MD, MS Assistant Professor of Clinical Medicine Indiana.
Judith Hsia Hormone Therapy Trial: Coronary Heart Disease & Fractures. Adverse effect for Breast Cancer? Calcium/Vitamin.
Chapter 10: Special Topics in Adults & Chronic Diseases: Nutrition and Public Health Judith Sharlin, PhD, RD.
Aging and Obesity Claire Zizza Tenth Annual Diabetes and Obesity Conference April 19, 2011.
1 Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators.
Cardiovascular Health and Risk Reduction in Children and Adolescents
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Oral Bisphosphonate and Breast Cancer: Prospective Results from the Women’s Health Initiative (WHI) Chlebowski RT et al. SABCS 2009; Abstract 21.
Slide Source: Lipids Online Slide Library Women’s Health Initiative: Trial of Estrogen plus Progestin 16,608 women randomized 16,608.
Risk factors for hip fracture in men l Low BMD and RF for low BMD l Previous fractures l Low body mass l Taller l Frequent falls and RF for falls.
Women’s Health Initiative: HRT Trial Baseline Data and Update on Follow-up Marcia L. Stefanick, Ph.D. Associate Professor of Medicine and of Obstetrics.
Health Coaching as a Strategy in the Team Practice Environment Leigh Ann Simmons, Ph.D. Assistant Professor, Medicine Senior Faculty Fellow for Clinical.
VA/DoD 2006 Clinical Practice Guideline For Screening and Management of Overweight and Obesity Guideline Summary: Key Elements.
The Cost Savings and Enhancements of a District’s Wellness Program A Case Study from Broward Presented by: Kay Blake, Training Supervisor Tina Severance-Fonte,
The Women’s Health Initiative Hormone Trials The Estrogen Only (women with a hysterectomy at baseline) and the Estrogen + Progestin (women with a uterus)
Chapter 15 Adolescent Nutrition: Conditions and Interventions
Background  Obesity is an extremely common problem ~ 1/3 of adult Americans are obese  Patients commonly ask physicians for advice on weight loss, yet.
What Participating Providers Must Tell Consumers.
National Heart, Lung, and Blood Institute Women’s Health Initiative Branch Jacques Rossouw, MD Chief, WHI Branch Program for Prevention and Population.
WHI CT Sample Size, Outcomes, Follow-up Women, aged Total CT = 68,133 Diet Modification (DM) Trial Primary Outcomes: Breast & Colorectal Cancer Secondary.
Diet & Type 2 Diabetes among American Indians: The Strong Family Heart Study Mandy Fretts, PhD MPH Nutritional Sciences Program Faculty Research Forum.
Clinical trial The Way We Make Progress Against Disease Prof. Ashry Gad Mohamed Prof. of Epidemiology College of Medicine & KKUH.
Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.
TWU Institute for Women’s Health Denton, Texas TWU Institute for Women’s Health TWU Institute for Women’s Health TWU Institute for Women’s Health IS THERE.
Plan For Change By Group 5. Identified problem: Obesity Ineffective Health Maintenance The people of Grand Traverse County have a lack of familiarity.
The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
MENAPOUSE. Natural Surgical premature RETROSPECTIVE Cessation of menstruation for 12 months In the absence of other physiological or psychological.
Menopausal Hormone Replacement Professor Gordana Prelevic, MD, DSc, FRCP Consultant Endocrinologist Royal Free Hampstead NHS Trust Whittington Health.
HERS, ERA and WHI: Recent trials in hormone replacement therapy Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology.
A Tool Kit for Battling Childhood Obesity:
CHAPTER 7: Obesity in Women. Introduction 68% of U.S. population is overweight or obese. Resulting medical and psychosocial difficulties can be debilitating.
Decoding the USPSTF By: Dr Vikram Arora Heritage Valley Health System.
Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Estrogen Plus Progestin and Breast Cancer Incidence.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Menopausal Hormone Therapy and Health Outcomes During.
Fast fOod Shops Significantly Impact Cardiovascular Karma - the FOSSICK IV Trial - Reddy M, Luque M, Ferrer Ferrer L, Koju R, Zaman MJ, Inspiron D, Caprnda.
The Rise and Fall of Hormone Replacement Therapy
A Low Carbohydrate Nutritional Program Improves Weight, Insulin, and Estrogenic Parameters in Obese Patients with Estrogen Receptor Positive Endometrial.
Weight Loss and Breast Cancer Incidence in Postmenopausal Women
San Antonio Breast Cancer Symposium, December 6-10, 2016
Marian L Neuhouser, PhD, RD
A Low-Fat Dietary Pattern Slows Progression of Diabetes: Results from the WHI Dietary Modification Trial Barbara V Howard, PhD Sr Scientist , MedStar.
Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
Section overview: Cardiometabolic risk reduction
Cardiovascular Disease in Women Module VI: Update on Menopausal Hormone Therapy and Selective Estrogen Receptor Modulators (SERMs) This slide set was.
Presentation transcript:

Women’s Health Initiative (WHI) Clinical Trials (CT) Observational Study (OS) Diet Modification (DM) Hormone Replacement Therapy (HRT) Calcium +Vitamin D (CaD)

WHI Organizational Chart NHLBI Director WHI Program Office WHI Steering Committee (SC) [40 Clinical Center (CC) PIs + CCC PI + PO rep.] Executive Committee (8 members) 4 Regional Groups of 9-12 CCs CC PIs; Lead Staff Groups (5/Reg) Working Group (NHLB Advisory Council) Data & Safety Monitoring Board Consortium of NIH Directors Advisory Committees DM, HRT, CaD, OS Special Pop.,Behavioral D&A, P&P, M&M Performance Monitoring Committee (PMC) Coordinating Center (CCC) FHCRC

HRT 27, 347 WHI CT Sample Size, Outcomes, Follow-up Women, aged Total CT = 68,133 DM 48,836 Diet Modification (DM) Trial Primary Outcomes: Breast & Colorectal Cancer Secondary Outcome: CHD Hormone (HRT) Trial Primary Outcome: CHD Secondary Outcomes: Hip Fracture, Breast Cancer 11.8% Overlap Average Follow-up 8.5 years Average 8.4 years

 USA National Cancer Act of 1971  Symposium on Nutrition and Causes of Cancer (AACR, 1975) National Cancer Institute & American Cancer Society  Diet, Nutrition, and Cancer, 1982, National Academy of Science  Food, Nutrition, and the Prevention of Cancer: a global perspective, World Cancer Research Fund,American Institute for Cancer Research (Evidence-based Report)  Scientific Evidence from many types of studies (Descriptive, Correlation, Special Exposure Groups, Migrant, Case-Control, Cohort, and Controlled Trials) was evaluated and rated as Convincing, Probable, Possible, or Insufficient to make judgements on causal relationships of dietary factors: decreases risk, increases risk, or no relationship Background for Diet/Cancer Hypothesis

WHI Diet Trial: Intervention Goals 40% of DM Sample (N=19,542) _ Total Fat Intake ≤ 20% of Daily Calories Saturated Fat ≤ 7% of Daily Calories _ Vegetable+Fruit intake ≥ 5 servings/day _ Grains,Cereals, Legumes ≥ 6 servings/day _ Maintain these dietary changes for 9 years

_LRC Prevalence Study (1983,1987) _Nurses’ Health Study (1985, 91) _Framingham Study (1985)-reversed _Nurses’ Health Study (1997) PERT _> 20 other Observational Studies HRT users vs nonusers (generally): fewer smokers, more physically active, leaner, healthier, at lower risk, more educated, higher SES _PEPI (1995) post-m. women, aged HRT improved HDL (ERT > PERT), LDL, and fibrinogen, but increased TG. _HERS (1998) women with CHD, aged No benefit from HRT (CEE+MPA) in reducing fatal+non-fatal MI; incr. DVT, PE, gallbladder disease _WHI (2005) Observational StudiesClinical Trials Background for HRT Study Hypothesis

WHI HRT Trial (N=27,347): Treatments WHI HRT Trial (N=27,347): Treatments Adherence < 80% initiates Intensive Adherence Program Estrogen with Progestin (50%) Conjugated Equine Estrogen (CEE) mg/day + Medroxyprogesterone Acetate mg/day (daily MPA) or Placebo (50%) Women with a Uterus (55% by design): Actual = 60.7% (N=16,608) Women with a Hysterectomy (45%): Actual = 39.3% (N=10,739) Estrogen only (50%) Conjugated Equine Estrogen (CEE) mg/day or Placebo (50%)

WHI CT: Baseline Age Distribution Mean ± S.D.: DM = 62.3 ± 6.9 ; HRT = 63.4 ± DM = 47%; HRT = 45% DM = 17%; HRT = 22% DM = 37%; HRT = 32%

TotalCT = 68,133 Minorities = 12,462 (18.3%) WHI CT (DM+HRT) : Minority Distribution Total CT = 68,133 Minorities = 12,462 (18.3%)

WHI CT (DM+HRT): Education Level 36.0%29.3%5.6% 65.1% %

WHI CT: Baseline Body Mass Index (kg/m 2 ) Mean BMI: DM = 29.1 ± 6.0 ; HRT = 29.1 ± 6.1 Percent Overweight or Obese Normal Overweight Obese I Obese II Obese III % Overwt or Obese DM: 74.0 HRT:73.3

WHI CT: Hormone Use & Uterine Status WHI CT: Hormone Use & Uterine Status History of Hormone UseHysterectomy Status

HRT 27,347 WHI CaD: Outcomes, Relationship to CT DM 48,836 Calcium + Vitamin D (CaD) Primary Outcome: Hip Fracture Secondary Outcomes: Other Fractures, Colorectal Cancer CaD 36,282 at 1st (or 2nd) Annual Visit Total CT = 68,133

WHI CaD Trial (N = 36,282): Treatments WHI CaD Trial (N = 36,282): Treatments Adherence < 80% initiates Intensive Adherence Program Supplement* (50%) Calcium carbonate 1000 mg/day + Vitamin D 400 IUs/day (daily RDA) or Placebo (50%) * Women may decide whether to take “Chewable” or “Swallowable” pill. Women are instructed to take one pill in the morning and one at night

WHI CT : Baseline Age Distribution Mean ± SD: DM = 62.3 ± 6.9; HRT = ± 7.2; CaD = 62.4 ± 6.9

WHI CT: Baseline Body Mass Index (kg/m 2 ) Mean ± SD : DM = 29.1 ± 6.0 ; HRT = 29.1 ± 6.1 ; CaD = 29.0 ± 5.9 Normal Overweight Obese I Obese II Obese III Percent Overweight or Obese DM: 74.0 HRT:73.3 CaD: 73.5

WHI CT: Hormone Use & Uterine Status History of Hormone UseHysterectomy Status

Recruitment of 165,000 Women aged 50-79* within 3-4 Yrs Recruitment of 165,000 Women aged 50-79* within 3-4 Yrs * Age-Specific Goals; CT Goal = 20% Minorities * Age-Specific Goals; CT Goal = 20% Minorities DM: Initial Diet ≥ 32% calories from fat; CT: medical, willingness DM: Initial Diet ≥ 32% calories from fat; CT: medical, willingness Screening & Baseline (Data Collection & Management) Screening & Baseline (Data Collection & Management) Randomization to CT or Enrollment into OS Randomization to CT or Enrollment into OS DM:40% Diet Change; 60% Diet Comparison (Control) DM:40% Diet Change; 60% Diet Comparison (Control) HRT:50% Active Hormone Pills*; 50% Placebo HRT:50% Active Hormone Pills*; 50% Placebo * *with Uterus: Estrogen+Progestin; Hysterectomy: Estrogen only CaD:50% Active Supplements; 50% Placebo [1st Ann. Visit] CaD:50% Active Supplements; 50% Placebo [1st Ann. Visit] Interventions (Adherence & Safety Concerns) Interventions (Adherence & Safety Concerns) Follow-up Visits (Retention) & Outcomes Ascertainment Follow-up Visits (Retention) & Outcomes Ascertainment WHI: Major Study Phases (Challenges)

HRT 27,347 (99.4%) WHI CT: Percent of Initial Goal; Overlap WHI CT: Percent of Initial Goal; Overlap Total CT = 68,133 (53.3% are in CaD)* Total CT = 68,133 (53.3% are in CaD)* DM 48,836 (101.7%) 11.8 % CT in DM+HRT 29.4% of HRT are in DM 16.5% of DM are in HRT CaD 36, % 58.8 % 7.3 % CT in DM+HRT+CaD 23.6%CT in HRT+CaD 37.0%CT in DM +CaD

Dietary Goals  Total Fat Intake ≤ 20% of Daily Calories Saturated Fat ≤ 7% of Daily Calories  Vegetables +Fruits ≥ 5 servings/day  Grain, Cereals, Legumes ≥ 6 servings/day  Maintain these dietary changes for 9 years Compliance Monitoring: Choice of Several Self-Monitoring Tools Class Attendance Goals (average 15 women/class)  Once a week for 6 weeks (Initial Sessions: Fat Goals, F&V)  Once every other week for 6 weeks (Grains, Roadblocks)  Once a month for 9 months (Behavioral Issues)  Maintenance: Once every 3 months until Study Ends WHI Diet Trial: Intervention Goals 40% of DM Sample (N=19,542)

WHI DM Change: Class Attendance, Fat Scores First Year Maintenance %

WHI DM Change Group: Daily Fat Grams Maintenance Average Goal = 25 grams Year 1

WHI DM Change Group: Food Scores Year 1 Maintenance Goal ≥ 6 grains/day ≥ 5 V&F/day

HRT participants are contacted semi-annually and attend annual follow-up clinic visits, involving:  Breast exam (Annual Mammogram is also required)  Pelvic Exam (for those with a uterus only)  PAP smear (Baseline & Years 3,6, 9)  ECG (Baseline & Years 3,6,9)  Pill Collection to assess Adherence  Risk counseling with any new information  A subset of women have endometrial aspirations and blood draws every 3 years (for later analyses) WHI: Annual Clinic Visits

WHI CT: Follow-up Clinic Visits

WHI CT: Adherence Monitoring AV AV AV AV Approx N ControlIntervention AV126,50018,000 AV28,6006,000 AV34,6003,100 AV45,0003,200 HRT Trial: Adherence Stopped< 80% Pills AV1-B10%13% AV2-AV19%13% AV3-AV27%13% AV4-AV36%13% CaD Trial: Adherence Stopped< 80% Pills AV2-AV110%28% AV3-AV26%26% AV4-AV35%23% DM Trial: C-I Difference % Fat Calories#F&VWt (kg)

Total CT = 68,133 HRT 27,347 WHI: Relationship of OS to CT DM 48,836 The Observational Study (OS) serves as a complement to the Clinical Trial. Total WHI Sample 161,809 Women screened for the DM or HRT CT could enroll in the OS,if they were ineligible for the CT, or chose not to join either DM or HRT. OS 93,676

WHI: Purpose of Observational StudyWHI: Purpose of Observational Study  Purpose of OS  To improve risk prediction of cardiovascular disease, cancers, fractures, and all-cause mortality in postmenopausal women  To create a resource of data and biological samples which can be used to identify new risk factors and/or disease biomarkers  To examine the impact of changes in lifestyle and risk factors on disease and mortality

WHI CT + OS: Baseline Diet (from FFQ) (DM Criteria Initial Diet ≥ 32% calories from fat) % Calories From Fat # Vegetable & Fruit Servings/Day DM HRT OS

WHI CT + OS: Baseline Age Distribution Mean ± SD: DM = 62.3 ± 6.9; HRT= ± 7.2; OS = 63.6 ± 7.4

WHI: Minority Distribution in CT and OS Total CT= 68,133 Total OS = 93,676 Percent Minority Women in Total CT and OS BlackHispanicAsian/PINative American Other CT (18.3%)OS (16.4%) PERCENT

WHI OS: Education Level 42.0%26.1%5.2% 68.7%

WHI CT + OS: Baseline Body Mass Index (kg/m 2 ) Mean BMI: DM = 29.1 ± 6.0; HRT = 29.1 ± 6.1; OS = 27.3 ± 5.9 Normal Overweight Obese I Obese II Obese III % Overwt or Obese DM: 74.0 HRT:73.3 OS: 59.2

WHI CT+ OS: Hormone Use & Uterine Status History of Hormone UseHysterectomy Status